More tools:Markets·Screener·Research Chat

Biogen Inc. Common Stock (BIIB) Financial Statements

Biogen Inc. Common Stock
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001S67826
XNAS · usd
191.95▼ 17.08 (-8.17%)
As of 2026-07-14
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA—
Financial Highlights
Revenue (TTM)$9.9B
Net Income (TTM)$1.4B
EBITDA—
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close209.03
Day's Range189.40 – 202.00
52-Week Range121.05 – 219.72
Volume3.82M
Avg Volume1.30M
Share Statistics
Shares Outstanding147.6M
Employees7,500
ExchangeXNAS
Listed1991-09-17

Key questions about Biogen Inc. Common Stock (BIIB)

What is Biogen Inc. Common Stock's Market Cap?
Biogen Inc. Common Stock's Market Cap is $28.3B, based on as-reported figures from SEC (XBRL) filings.
What is Biogen Inc. Common Stock's Enterprise Value?
Biogen Inc. Common Stock's Enterprise Value is $34.1B, based on as-reported figures from SEC (XBRL) filings.
What is Biogen Inc. Common Stock's Trailing P/E?
Biogen Inc. Common Stock's Trailing P/E is 20.7×, based on as-reported figures from SEC (XBRL) filings.
What is Biogen Inc. Common Stock's Price / Sales?
Biogen Inc. Common Stock's Price / Sales is 2.9×, based on as-reported figures from SEC (XBRL) filings.
What is Biogen Inc. Common Stock's EV / Revenue?
Biogen Inc. Common Stock's EV / Revenue is 3.4×, based on as-reported figures from SEC (XBRL) filings.
What is Biogen Inc. Common Stock's Revenue (TTM)?
Biogen Inc. Common Stock's Revenue (TTM) is $9.9B, based on as-reported figures from SEC (XBRL) filings.
What is Biogen Inc. Common Stock's Net Income (TTM)?
Biogen Inc. Common Stock's Net Income (TTM) is $1.4B, based on as-reported figures from SEC (XBRL) filings.
What is Biogen Inc. Common Stock's Diluted EPS (TTM)?
Biogen Inc. Common Stock's Diluted EPS (TTM) is 9.29, based on as-reported figures from SEC (XBRL) filings.
What is Biogen Inc. Common Stock's Net Debt?
Biogen Inc. Common Stock's Net Debt is $3.3B, based on as-reported figures from SEC (XBRL) filings.
Loading Income Statement…
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022
Revenue:
Product revenue, net
Alzheimer's collaboration revenue—
Contract manufacturing, royalty and other revenue—
Total revenue
YoY growth+1.9%-7.1%+2.8%+7.3%
Cost and expense:
Cost of sales, excluding amortization and impairment of acquired intangible assets
Research and development
Acquired in-process research and development, upfront and milestone expense—
Selling, general and administrative
Amortization and impairment of acquired intangible assets
Collaboration profit sharing/(loss reimbursement)—
(Gain) loss on fair value remeasurement of contingent consideration—
Restructuring charges
Other (income) expense, net—
Total cost and expense
% of revenue84.8%102.5%78.0%71.9%
Income (loss) before income taxes
Income tax expense (benefit)
Net income attributable to Biogen Inc.
% of revenue12.9%-2.1%18.4%24.0%
Net income per share:
Basic earnings per share attributable to Biogen Inc.
Diluted earnings per share attributable to Biogen Inc.
Weighted-average shares used in calculating:
Basic earnings per share attributable to Biogen Inc.
Diluted earnings per share attributable to Biogen Inc.